Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics - Wikidata - wikimedia - TriplyDB

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

http://www.wikidata.org/entity/Q26776391

about

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Precision oncology: neither a silver bullet nor a dream.Priapism as the Presenting Manifestation of Multiple Myeloma.

P2860

Q30275582-BF3D1890-AC91-483D-8AB1-48F2B5D24D1A Q34555067-D8830A3B-A6E4-44D1-9B27-89DA93101C71 Q47737073-26EC43EC-38BE-441F-9EAF-934AFE2F3CD5 Q54946156-22F054DF-012E-4929-A5F5-5E7B01F23ACD

P2860

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

http://www.wikidata.org/entity/Q26776391

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@ast

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@en

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@nl

type

label

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@ast

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@en

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@nl

prefLabel

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@ast

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@en

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@nl

P1433

Q26776391-EB25F58E-BB68-482B-8F35-278A2DA35CAA

P1476

Q26776391-FC5DA310-E6EF-4023-9F20-481ACAC37858

P2093

Q26776391-2FCBE1DF-6F0D-4BAA-838B-A10A92F264B7

P275

Q26776391-86F40D4B-B76B-45C8-BBED-D3DD2AFD7328

P2860

Q26776391-028E5CF2-3D23-4E8B-90AF-934651EE2451

Q26776391-06A4E72E-B62C-4614-A933-923D8A10DC96

Q26776391-0BA429B6-031B-4C86-B458-669CBE5C9774

Q26776391-177290EA-CC3A-4EF4-B657-CFEE2756CFDC

Q26776391-1C9E24D8-D93E-4E05-8473-05CF94D9E484

Q26776391-216D85FE-621F-4489-A1FA-7AAD16A75CFB

Q26776391-285A8423-A658-4967-8707-D2E4CF4D525D

Q26776391-29D135C2-BDB7-4BBB-A8BB-607D2CCEB184

Q26776391-2A2AC941-6D65-4312-A11F-171AD5AAB906

Q26776391-34C0DD11-79BE-4925-9962-B2C88BD728F6

P304

Q26776391-4CE1A522-AE12-4BBD-8756-BDE713CC45B5

P31

Q26776391-239FA76E-9F16-4E14-9B4C-9CAB63D2FD13

Q26776391-B3C8D62B-EB17-4D17-B1CD-66CB582E1670

P356

Q26776391-6D4C0063-99E7-400B-96E9-B1E7786FF453

P407

Q26776391-15C884CF-2AEC-465D-9C97-6835D7EAB4E9

P433

Q26776391-1B840914-B4A7-43AC-960F-93CE0DAACC86

P478

Q26776391-675D52A7-A08C-428A-9BC2-A00DAB7A91B3

P50

Q26776391-73F4DC81-F4ED-466C-B5F0-A49855AAFEE4

Q26776391-E5FBC150-52D2-4DA8-8337-B35E2B795A8D

P5008

Q26776391-BD44B945-58F7-425A-968A-116034C3C1E9

P577

Q26776391-33AF1F87-AC4F-46D8-A21E-F319286D59E0

Q26776391-9818AE32-0DAE-4D7A-A2F0-902CB2F4176A

P5875

Q26776391-728CDDCF-62D8-4F82-94BF-8C5018718DED

P698

Q26776391-E26E2CE1-0E79-4C12-AB0F-63D722F91A74

P921

Q26776391-1A00E7DC-C79E-4B73-B42D-9F3E29F9B3C1

Q26776391-39D9DC66-BE7A-466C-9A3B-3E58AABA683B

Q26776391-3A7ADB67-EC63-4A30-8AA3-745FB929DB75

Q26776391-948D9DC5-E481-4EBF-BF9E-37EAE5C09A19

Q26776391-CF921699-686D-4A3B-904E-682A35113A16

P932

Q26776391-7CAD7E51-7B7C-4745-8C11-9537DAC8C4C8

P356

P1433

Annals of Oncology

P1476

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

@en

P2093

I M Ghobrial

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden

Thalidomide and rituximab in Waldenstrom macroglobulinemia

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

P304

233-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV572

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P5008

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284547107

http://www.w3.org/2001/XMLSchema#string

P698

26598544

http://www.w3.org/2001/XMLSchema#string

P921

Waldenström's macroglobulinemia

mechanism of action

monoclonal antibody

P932

4722893

http://www.w3.org/2001/XMLSchema#string